 Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. Nasdaq: VXRT for the manufacture of Vaxarts oral vaccine candidate for COVID-19. 